Xbrane Biopharma: Follow Up Note – Indicatively Raised Fair Value - Redeye

Following Monday's announcement of the Xcimzane licensing deal with Biogen, Redeye is convinced that Xbrane shares are currently trading at a substantial discount and, therefore, indicatively raises its fair value.

Länk till analysen i sin helhet: https://www.redeye.se/research/832209/xbrane-biopharma-short-follow-up-indicatively-raised-fair-value?utm_source=finwire&utm_medium=RSS